Icon

KYXATA (NDA219921)- (20MG/2ML (10MG/ML),80MG/8ML (10MG/ML),500MG/50ML (10MG/ML))

CARBOPLATIN AVYXA HOLDINGS
20MG/2ML (10MG/ML),80MG/8ML (10MG/ML),500MG/50ML (10MG/ML)
No Yes
2045-Apr-01 Expired
None None
None No
KYXATA is a platinum-based drug indicated in adults: • As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma. • As a single-agent for the treatment of ovarian carcinoma recurrent after prior chemotherapy.
0 0 0
Total Other Developers None
Drugs with Suitability No
20MG/2ML (10MG/ML) ** ** - - -
80MG/8ML (10MG/ML) ** ** - - -
500MG/50ML (10MG/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.